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Abstract
Background: Patients with recessive dystrophic epider-
molysis bullosa (RDEB) have deficiencies of collagen
type VII and have elevated levels of fibroblast collage-
nase, and a greatly increased risk of cutaneous squamous
cell carcinoma. Patients with other genetic blistering dis-
orders do not have elevated collagenase or an increased
risk of squamous cell carcinoma, despite chronic wound-
ing. The connection between collagen type VII defi-
ciency, increased collagenase, and squamous cell carci-
noma is not understood.
Materials and Methods: Urine from 81 patients with
RDEB (39 patients), junctional epidermolysis bullosa
(JEB; 12 patients), and epidermolysis bullosa simplex
(EBS; 30 patients), as well as unaffected family members
of RDEB patients (33 patients), was tested for the pres-
ence of basic fibroblast growth factor (bFGF) using a
sensitive radioimmunoassay. These patients induded many
who were enrolled in the Epidermolysis Bullosa Registry
and others who were referred by their physicians.
Results: Fifty-one percent of patients with RDEB had
elevated levels (>5000 pg/g) of urinary bFGF. In con-
trast, none of the patients with JEB had elevated levels of
bFGF. Twenty-one percent of clinically unaffected family
members had elevated levels of bFGF, and 13% of pa-
tients with EBS had elevated levels of bFGF. The fre-
quency of elevated bFGF values among all groups was
statistically significant (p = 0.002), and the levels of bFGF
in RDEB patients were significantly elevated compared
with those of other groups (p < 0.05).
Conclusions: We have found that patients with RDEB
have elevated levels of bFGF, which may contribute to
increased fibroblast collagenase and the development of
squamous cell carcinoma. These results suggest a novel
treatment for RDEB, namely, angiogenesis inhibitors,
which may antagonize the effects of bFGF in this disor-
der. There are currently no other means of treatment for
this disorder, which has a high morbidity and mortality
rate.
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Introduction
Recessive dystrophic epidermolysis bullosa
(RDEB) is usually a severe and often fatal genetic
disease characterized by mechanically fragile
skin and subepidermal blistering (1-4). Patients
with RDEB have elevated levels of fibroblast-
derived collagenase and a high incidence of
squamous cell carcinoma, neither of which is
observed in the two other major epidermolysis
bullosa subtypes, junctional epidermolysis bul-
losa (JEB) and epidermolysis bullosa simplex
(EBS) (5,6). Clinically, RDEB is characterized by
a high degree of morbidity from scarring, chronic
erosions, chronic severe pruritus, fusion of fin-
gers, esophageal stenosis, recurrent infection,
and squamous cell carcinoma (1-4). Patients
with all major subtypes of RDEB have greatly
diminished levels of collagen type VII. This is a
component of anchoring fibrils, which are struc-
tures that attach the epidermis to the dermis
(7-10). We found that a patient with severe
RDEB and bilateral above-the-elbow amputa-
tions for recurrent squamous cell carcinoma had
elevated levels of urinary basic fibroblast growth
factor (bFGF). To assess the role of bFGF in this
genetic bullous disease, urine samples from pa-
tients with RDEB, JEB, EBS, and unaffected fam-
ily members were identically screened.
Materials and Methods
Urine samples from patients with RDEB (n = 39)
and their parents and unaffected siblings (n =
33) were analyzed for the presence of bFGF. As
potential controls, urine from patients with JEB
(n = 12) and EBS (n = 30) was similarly ana-
lyzed. Samples were refrigerated at 40C during
transit and stored at -80°C prior to bFGF radio-
immunoassay (11).
A 20-ml aliquot of thawed urine was centri-
fuged at 2300 rpm for 8 min at 40C. The super-
natant was filtered using a filter with a pore size
of 1.2 ,tm. The sample was then analyzed using
a radioimmunoassay for bFGF according to the
manufacturer's instructions (Human bFGF,
Quantikine HS, R+D Systems, Minneapolis,
MN).
We used the Kruskal-Wallis test to deter-
mine overall differences in the levels of bFGF
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among EB groups, and Duncan's Multiple Range
Test on ranked bFGF values to identify specific
differences.
Immunohistochemical Staining
Sections from a bullae from a patient with RDEB
were deparaffinized and stained with a rabbit
polyclonal antibody against von Willebrand fac-
tor (Dako, Carpentaria, CA), at a dilution of
1/100. A secondary mouse anti-rabbit IgG anti-
body conjugated to diaminobenzidine was incu-
bated at a concentration of 1/50, and the slide
was stained according to the manufacturer's
directions.
Results
Over 50% of patients with RDEB were found to
have levels of urinary bFGF greater than 5000
pg/gram of urine. Normal values of urinary bFGF
are less than 5000 pg/g (1 1). In contrast, none of
the patients with JEB had urinary bFGF values
greater than 5000 pg/g of urine. Seven out of
thirty-three unaffected family members of RDEB
had urinary bFGF above 5000 pg/g (21 %), and 4
out of 30 patients with epidermolysis bullosa
simplex had urinary bFGF levels above 5000
pg/g (13%). The Kruskall-Wallis test showed
that there was statistical significance between
groups, with one group being significantly differ-
ent from all other groups (p = 0.002). The Dun-
can's Multiple Range test showed that bFGF val-
ues in RDEB significantly differed from those of
the other three groups (p < 0.05) (Fig. 1,
Table 1). In contrast, values from non-RDEB
sources were not significantly different from
each other. No correlation was seen between the
extent of body surface involvement and the pres-
ence of squamous cell carcinoma in RDEB
patients.
Discussion
Epidermolysis bullosa comprises a heterogenous
group of genetic disorders of the skin character-
ized by blister formation within different layers
of the skin. RDEB has been linked to defects in
collagen type VII, and it is usually characterized
by severe cutaneous and extracutaneous disease
activity and a highly increased risk of cutaneous
squamous cell carcinoma (1-6). Whereas both
RDEB and JEB can be associated with severe












FIG. 1. Comparison of urinary bFGF values be-
tween patients with recessive dystrophic epi-
dermolysis bullosa (RDEB), unaffected family
members of patients with RDEB (family), junc-
tional epidermolysis bullosa (JEB), and epider-
molysis bullosa simplex (EBS). The top dots on
the bar graph represent extreme values, the upper
side of the rectangle represents the upper quartile
values, the bar inside the rectangle represents the
median value, and the lower side of the box repre-
sents the lower quartile. The error bars above and
below each rectangle represent 1.5 X the interquar-
tile range drawn towards the nearest data point.
morbidity and mortality, only RDEB is associated
with elevated levels of collagenase and an ex-
tremely high incidence of cutaneous squamous
cell carcinoma. This study provides a potential
explanation for these findings.
Prior to the discovery of collagen VII defects
in RDEB, these patients had been shown to have
elevated collagenase activity both in dermal ex-
tracts and in supernatants from fibroblast cul-
tures (12,13). Based on this finding, phenytoin, a
weak inhibitor of collagenase, was tested for its
ability to ameliorate the symptoms (14-16). Ini-
tial studies appeared to demonstrate a beneficial
Table 1. Range of urinary bFGF values
bFGF Values (pg/g)
N (Number of
Diagnosis Median Range patients)
RDEB 5021 609-78297 39
Family 2396 422-11916 33
JEB 2785 351-4604 12
EBS 2830 311-29407 30
effect, although a double-blinded, crossover, pla-
cebo-controlled larger study failed to confirm
any significant overall benefit (17). In addition,
no mutations in collagenase genes were discov-
ered in RDEB. While the association between
alteration in anchoring fibrils, blister formation,
and type VII collagen mutations is apparent, the
connection between these mutations and the
presence of elevated collagenase and squamous
cell carcinomas is not readily apparent.
We have discovered that patients with RDEB
have elevations of basic fibroblast growth factor
in their urine. Examination of the dermis in a
patient with RDEB and elevated bFGF reveals
numerous microvessels beneath a typical bulla
(Fig. 2). The subepidermal location of bullae at
the sites where heparan sulfate proteoglycans
bind bFGF may contribute to release of bFGF.
bFGF has several activities that may contrib-
ute to the pathogenesis of RDEB. First, it is a
stimulant of collagenase synthesis, which may
account for the elevated collagenase and perpet-
uation of blistering observed in these patients
(12). bFGF is also a potent angiogenic factor,
which may enhance the growth of squamous cell
carcinoma (18,19). Finally, bFGF is a keratino-












RDEB. (AHematoxyicli and emuosinstanofheaibull
from a patient with RDEB (XI100); (B) von Wille-
brand staining of the dermis from the same section.
The black-stained lumens represent microvessels
(XI100). The bars represent 50 ji~m.
keratinocytes may predispose to squamous cell
carcinoma (20). Overexpression of collagenase in
the skin of transgenic mice causes an elevated
incidence of cutaneous squamous cell carcinoma
(21). Thus elevation of bFGF and collagenase
may contribute to cutaneous carcinogenesis.
We did not observe a strict correlation be-
tween the presence of squamous cell carcinoma
and bFGF values. The measurements of bFGF in
this study were at a single time point. Continued
observation of this cohort over a period of years
is needed to determine whether bFGF levels cor-
relate with the eventual development of cutane-
ous squamous cell carcinoma.
We did not find urinary bFGF elevated in all
RDEB patients. We postulate at least two possible
explanations. First, bFGF may be present in high
levels at skin lesions, and once local binding is
saturated, it may enter the systemic circulation.
Sonme of ouir patients, may not have ha;d fuilly
VII, which cause variable levels of basement
membrane disruption, may result in differing
rates of release of bFGF. We feel that the release
of bFGF is not strictly a function of wounding,
however, as patients with JEB have equally se-
vere cutaneous wounding but lack elevated
bFGF levels.
These results suggest strategies that may be
useful in alleviating the morbidity of RDEB. In-
hibition of bFGF in tumor cells by a interferon
has been suggested as a potential mechanism for
the anti-tumor activity of a interferon, and this
activity may be of benefit in RDEB (22). Also,
inhibitors of bFGF activity, such as tyrosine ki-
nase inhibitors, may antagonize bFGF-mediated
collagenase expression (23). Finally, potent and
specific inhibitors of collagenase may be useful in
the prevention of bullae formation and scarring
(24).
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